| Active, not recruiting | 2/3 | 360 | Europe, Canada, US, RoW | Unesbulin, PTC596, Dacarbazine, DTIC, Placebo | PTC Therapeutics, PTC Therapeutics, Inc. | Leiomyosarcoma | 06/24 | 06/24 | | |
NCT04551430: Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma |
|
|
| Active, not recruiting | 2 | 105 | US | Cabozantinib, Nivolumab, Opdivo, Ipilimumab, Yervoy | Washington University School of Medicine, Exelixis, Bristol-Myers Squibb | Metastatic Soft-tissue Sarcoma | 06/24 | 06/30 | | |
NCT04602117: ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer |
|
|
| Withdrawn | 1 | 27 | US | Vic-trastuzumab duocarmazine (SYD985) + paclitaxel, SYD985, paclitaxel, SYD-985, Taxol, [vic-] trastuzumab duocarmazine | QuantumLeap Healthcare Collaborative, Byondis B.V. | HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985, Vic-trastuzumab Duocarmazine, Metastatic Cancer, Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic, HER2 Low Breast Cancer, GastroEsophageal Cancer, Gastroesophageal Adenocarcinoma, Endometrium Tumor, Ovarian Cancer, Ovarian Carcinoma, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2 Low HR Positive, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Bladder Cancer | 11/21 | 11/21 | | |
